Does Simponi Cause Tuberculosis?
Simponi (golimumab) does not directly cause tuberculosis (TB), but it significantly raises the risk of reactivating latent TB infection by suppressing the immune system. The drug is a TNF-alpha inhibitor, which blocks tumor necrosis factor—a protein essential for fighting infections like TB. Patients with latent TB can develop active disease during treatment.[1][2]
Black Box Warning on Infections
Simponi carries FDA-mandated black box warnings for serious infections, including TB. Clinical trials and post-marketing reports documented cases of active TB, often in patients unknowingly harboring latent TB. The label states: "Tuberculosis (TB) may occur during treatment... Test for latent TB before starting."[1]
TB Screening Before Starting Treatment
Guidelines require screening all patients for latent TB via tuberculin skin test, interferon-gamma release assay (IGRA), or chest X-ray prior to Simponi initiation. Positive latent TB must be treated first. Janssen, the manufacturer, recommends annual re-testing in high-risk groups like those in endemic areas.[1][2]
Real-World TB Risk Data
In pivotal trials (GO-FORWARD, GO-BEFORE), no TB cases occurred among screened patients, but post-approval surveillance revealed TB incidence rates of 0.1-0.5 per 100 patient-years—higher than the general population but lower than untreated rheumatoid arthritis patients with similar risks.[3] A 2018 meta-analysis of TNF inhibitors found Simponi associated with 4-5 TB cases per 10,000 patient-years, comparable to other drugs in its class like Humira or Enbrel.[4]
What If You Already Have Latent TB?
Untreated latent TB has a 5-10% lifetime reactivation risk, but Simponi increases this dramatically—up to 10-fold in studies. Prophylactic treatment with isoniazid or rifampin for 3-9 months is standard before starting. Delaying Simponi allows TB treatment without compromising arthritis or psoriasis control.[2][5]
TB Cases During or After Simponi Use
Most reported TB cases are pulmonary, but extrapulmonary forms (e.g., lymph node, disseminated) occur. Symptoms include cough, fever, weight loss. Risk persists for months after stopping due to prolonged drug half-life (2 weeks). Discontinue Simponi if active TB develops.[1]
How Does Simponi Compare to Other TNF Inhibitors on TB Risk?
| Drug | TB Incidence (per 10,000 patient-years) | Notes |
|------|-----------------------------------------|-------|
| Simponi | 4-5 | Similar to class average[4] |
| Humira (adalimumab) | 5-7 | Slightly higher in some registries[3] |
| Enbrel (etanercept) | 3-4 | Lower skin test conversion rates[4] |
| Remicade (infliximab) | 6-9 | Highest among originators[3] |
All require TB screening; monoclonal antibodies like Simponi may pose marginally higher risk than etanercept.[4]
Patient Reports and Long-Term Concerns
Online forums (e.g., Drugs.com, Reddit) feature patient stories of TB reactivation despite screening, often in immigrants from high-TB regions. Long-term users face cumulative risk, though biologics-naive patients on monotherapy have lower rates. Consult rheumatologists for personalized risk assessment.[6]
[1]: Simponi Prescribing Information (FDA)
[2]: CDC Guidelines on TNF Inhibitors and TB
[3]: Askling et al., Annals of Rheumatic Diseases (2009)
[4]: Cantini et al., Seminars in Arthritis and Rheumatism (2018)
[5]: EULAR Recommendations (2020)
[6]: Drugs.com Simponi Reviews